Hong Zhao - SciClone Pharmaceuticals Insider

SCLN -- USA Stock  

USD 11.15  0.00  0.00%

  CEO
Mr. Hong Zhao was appointed as Chief Executive Officer China Operations of Sciclone Pharmaceuticals, Inc., effective April 01, 2013. Mr. Zhao joined SciClone as Chief Executive Officer, China Operations, in April 2013. Prior to SciClone, from 2011 to 2013, Mr. Zhao served as Executive Vice President of Simcere Pharmaceutical Group, a manufacturer and supplier of pharmaceuticals in China, where he was responsible for all business operations and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, from 1999 to 2011, Mr. Zhao held various positions at Novartis China, a health care products company, including most recently, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai
Age: 50  CEO Since 2013      
650-358-3456  www.sciclone.com
Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School in Shanghai.

Hong Zhao Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.28 % which means that it generated profit of $11.28 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 19.56 % meaning that it created $19.56 on every $100 dollars invested by stockholders.

Similar Executives

Found 4 records

CEO Since

Juan AlaixZoetis
2012
Ellen ZanePAREXEL International Corporati
2006
Leonard SchleiferRegeneron Pharmaceuticals
1994
William NieburOrigin Agritech Limited
2016

Entity Summary

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals (SCLN) is traded on NASDAQ in USA. It is located in 950 Tower Lane, Suite 900, Foster City, CA 94404, United States and employs 590 people.

SciClone Pharmaceuticals Leadership Team

Charles Meng, VP of Compliance and General Counsel
Richard Hawkins, Independent Director
Gregg Lapointe, Independent Director
Hong Zhao, CEO of China Operations
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary
Nancy Chang, Director
Anthony Lapointe, Independent Director
Lan Xie, VP of Fin. and CFO of China Operations
Raymond Low, Vice President - Finance, Controller
Robert King, Senior Vice President - Product Development and Supply Chain
Simon Li, Independent Director
Jon Saxe, Independent Chairman of the Board
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee

Stock Performance Indicators

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Portfolio Rebalancing
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
3 days ago
Traded for 156.0
CRM   
Purchased a lot of shares of
3 days ago
Traded for 156.0
F   
Purchased over 300 shares of
3 days ago
Traded for 9.81
C   
Purchased over 40 shares of
3 days ago
Traded for 74.735
GM   
Purchased over 70 shares of
3 days ago
Traded for 36.08
Also please take a look at World Market Map. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Search macroaxis.com